

Global Perspectives on Optimal Treatment for HR+, HER2- Advanced Breast Cancer

Learning Objectives

- Evaluate recent data on treatment combinations from clinical trials for HR+ advanced breast cancer
- Discuss ongoing research strategies to address areas such as sequence of therapeutic agents and patient selection for clinical trials
- Understand differences in the management of HR+ advanced breast cancer by country or region with respect to diagnosis, available treatments, and determining the best option for patients

20 October 2018
 13:00 – 14:30
 Hall B3 – Room 20
 Messe Munich
 Munich, Germany

Faculty

Chair Martine Piccart
Moderator Andreas Hartkopf
Panelists Bella Kaufman
 Ahmed Saadeddin
 Yoon-Sim Yap

	TOPIC	FACULTY	
13:00 - 13:10	Welcome and Introduction	Chair: Martine Piccart	
13:10 – 14:25	Metastatic Breast Cancer: First-Line Treatment Options	Moderator: Andreas Hartkopf Panelists: All faculty	PANEL DISCUSSION
	Beyond First-Line: Treatment Sequencing		
	Beyond Clinical Efficacy: Monitoring and Management of Patients		
14:25 - 14:30	Closing Remarks	Chair: Martine Piccart	



This scientific information may include data/information on investigational uses of compounds/drugs that have not yet been approved by regulatory authorities. This program and/or material was developed for use outside of the US, intended for non-US HCPs, and is to be used in accordance with local laws and regulations.